close

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma under a special protocol assessment. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; and SGN-70, a humanized anti-CD70 antibody. In addition, its product candidates in development comprise SGN-75 for CD70-positive hematologic malignancies and solid tumors; AGS-5ADC for solid tumors; and SGN-19A for CD19-positive hematologic malignancies. It has a collaboration agreement with Genentech, Inc. to develop and commercialize Dacetuzumab; with Genentech, Inc., Bayer Pharmaceuticals Corporation, CuraGen Corporation, Progenics Pharmaceuticals, Inc., Daiichi Sankyo Co., Ltd., and MedImmune Inc. for the company's antibody-drug conjugates (ADC) technology; and an ADC co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	18.71
Volume	639074
Volume Avg	(mio) 1.32
52 Week High	22.40
52 Week Low	12.29
PE	N/A
PE (group average)	39
EPS Year	-1.34
EPS change Q/Q	-11.76%
EPS change Q/Q Yr ago	1000%
EPS change Q/Q next Q est	-100%
EPS change Y/Y	-54.72%
REV change Q/Q	50.62%
REV change Q/Q Yr ago	-73.76%
EPS next Q est	-0.15
EPS next Y est	-0.28
Divident Annual	0.00
Dividend Yield	0%